The benefits of the multi-target approach in drug design and discovery

L. Michel Espinoza-Fonseca

Research output: Contribution to journalEditorialpeer-review

141 Scopus citations


Promiscuous binding has been considered to be a problem in the design and development of new drugs against a given disease. However, promiscuity in molecular recognition is not all bad news, and scientists are currently taking advantage of the emerging 'promiscuous binding' or 'multi-target approach' in medicinal chemistry.

Original languageEnglish (US)
Pages (from-to)896-897
Number of pages2
JournalBioorganic and Medicinal Chemistry
Issue number4
StatePublished - Feb 15 2006

Bibliographical note

Funding Information:
The author thanks the referees for their useful comments and suggestions, and Asya Varbanova for the review of the manuscript draft. The author’s research is supported by a research stipend granted by the Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota.


  • Alzheimer's disease
  • Cancer
  • Drug design
  • Promiscuous drug


Dive into the research topics of 'The benefits of the multi-target approach in drug design and discovery'. Together they form a unique fingerprint.

Cite this